5-FU resistant colorectal cancer cells possess improved invasiveness and βIII-tubulin expression
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16314Keywords:
5-fluorouracil, chemoresistance, colorectal cancer., invasiveness, βIII-tubulinAbstract
Summary. Background: Elevated βIII-tubulin levels are associated with resistance to a broad spectrum of drugs in different carcinomas and with poor prognosis of various epithelial cancers. 5-Fluorouracil (5-FU) is a widely used standard drug in chemotherapeutic regimens for colorectal cancer treatment, although the resistance to 5-FU is a major obstacle to successful therapy. Aim: The aim of the study was to compare the invasive and adhesion properties and the expression levels of βIII-tubulin in a 5-fluorouracil (5-FU)-resistant colorectal cancer (CRC) cell line HCT116 and parental cells. Materials and Methods: The 5-FU-resistant cell line was established by continuous stepwise selection with increasing concentrations of 5-FU. Cell viability and properties were evaluated using MTT, adhesion and Transwell invasion assays, respectively. The expression of βIII-tubulin was revealed by immunoblot and immunofluorescence. Results: The derivative line is 25-fold more resistant to 5-FU and characterized by altered cell morphology. Twice as many cells of the 5-FU-resistant line fail to adhere as compared to the parental cell line. 5-FU-resistant cells are characterized by enhanced invasiveness, accompanied with the increased βIII-tubulin expression. In addition, we found that loss of βIII-tubulin expression was correlated with loss of 5-FU resistance. Conclusion: Our results indicate that even though 5-FU does not target microtubules, there appears to be a correlation between βIII-tubulin expression and resistance to 5-FU that is particularly important with regard to invasiveness. These findings indicate a possible contribution of βIII-tubulin to 5-FU resistance in vivo.
References
Cancer Today website: http://gco.iarc.fr.
Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases — a population-based study on incidence, management and survival. BMC Cancer 2018; 18: 78.
Iqbal S, Stoehlniacher J, Lenz H. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 2004; 22: 762–73.
de Angelis P, Fjell B, Kravik K, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004; 24: 1279–88.
De Angelis P, Svendsrud D, Kravik K, et al. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 2006; 5: 20.
De Angelis P, Kravik K, Tunheim S, et al. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 2004; 3: 11.
Shen W, Pang H, Liu J, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res 2014; 22: 47–55.
Zhang W, Feng M, Zheng G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012; 417: 679–85.
Harada K, Ferdous T, Ueyama Y. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol 2014; 44: 1302–8.
Shen W, Pang H, Liu J, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res 2014; 22: 47–55.
Cirillo L, Gotta M, Meraldi P. The elephant in the room: The role of microtubules in cancer. Adv Exp Med Biol 2017; 1002: 93–124.
Parker A, Kavallaris M, McCarroll J. Microtubules and their role in cellular stress in cancer. Front Oncol 2014; 4: 153.
Mariani M, Karki R, Spennato M, et al. Class III β-tubulin in normal and cancer tissues. Gene 2015; 563: 109–14.
Katsetos C, Herman M, Mörk S. Class III β-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 77–96.
Karki R, Mariani M, Andreoli M, et al. βIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin Ther Targets 2013; 17: 461–72.
Li W, Zhai B, Zhi H, et al. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7. Tumour Biol 2014; 35: 8883–91.
Gan P, McCarroll J, Byrne F, et al. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011; 6: e21717.
English D, Roque D, Santin A. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? Expert Rev Anticancer Ther 2013; 13: 63–74.
Longley D, Wilson T, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838–48.
Portyanko A, Kovalev P, Gorgun J, et al. βIII-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 2009; 454: 541–8.
Roque D, Bellone S, English D, et al. Tubulin- beta-III overexpression by uterine serous carcinomas is a marker for poor over- all survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013; 119: 2582–92.
De Donato M, Mariani M, Petrella L, et al. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012; 227: 1034–41.
Su D, Smith S, Preti M, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 2453–63.
Hwang J, Hong J, Kim K, et al. Class III beta- tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer 2013; 13: 431.
Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9: 2992–7.
Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol Suppl 2005; 4: iv14-9.
Levallet G, Bergot E, Antoine M, et al. Intergroupe Francophone de Cancérologie Thoracique (IFCT): High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 2012; 11: 1203–13.
Seve P, Isaac S, Tredan O, et al. Expression of class III beta-tubulin is predictive of patient outcome in patients with non- small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481–6.
Köhne CH. Current stages of adjuvant treatment of colon cancer. Ann Oncol 2012; 23: x71–6.
Longley D, Harkin D, Johnston P. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–8.
Peters G, Backus H, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194–205.
Valastyan S, Weinberg R. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011; 147: 275–92.
Uchibori K, Kasamatsu A, Sunaga M, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 2012; 40: 1005–10.
Littl M, Ludueña R. Structural differences between b1- and b2-tubulins: implications for microtubule assembly and colchicine binding. EMBO J 1985; 4: 51–6.
Bai R, Lin C, Nguyen N, et al. Identification of the cysteine residue of beta-tubulin affected by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography. Biochemistry 1989; 28: 5606–12.
Punnonen K, Ahotupa M, Asaishi K, et al. Antioxidant activities and oxidative stress in human breast cancer. J Cancer Res Clin Oncol 1994; 120: 374–7.
Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000; 92: 1926–34.
Portakal O, Ozkaya O, Erden I, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000; 33: 279–84.
Ray G, Batra S, Shukla N, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000; 59: 163–70.
Gilkes D, Semenza G. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 2013; 9: 1623–36.
Landino L, Hasan R, McGaw A, et al. Peroxynitrite oxidation of tubulin sulfhydryls inhibits microtubule polymerization. Arch Biochem Biophys 2002: 398: 213–20.
Landino L, Skreslet T, Alston J. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem 2004; 279: 35101–5.
Clark H, Hagedorn T, Landino L. Hypothiocyanous acid oxidation of tubulin cysteines inhibits microtubule polymerization. Arch Bioch Bioph 2014; 541: 67–73.
Joe P, Banerjee A, Luduena R. The roles of cys124 and ser239 in the functional properties of human beta III tubulin. Cell Motil Cytoskeleton 2008; 65: 476–86.
Khan I, Luduena R. Phosphorylation of βIII-tubulin. Biochemistry 1996; 35: 3704–11.
Tsourlakis M, Weigand P, Grupp K, et al. βIII-Tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol 2014; 184: 609–18.
McCarroll J, Gan P, Erlich R, et al. TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res 2015; 75: 415–25.
Dumontet C, Jordan M. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790–803.
Katsetos C, Reginato M, Baas P, et al. Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol 2015; 22: 49–72.
Nepali K, Ojha R, Lee H, et al. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opin Investig Drugs 2016; 8: 917–36.
Shibazaki M, Maesawa C, Akasaka K, et al. Transcriptional and post-transcriptional regulation of βIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells. Int J Oncol 2012; 40: 695–702.
Parker A, Turner N, McCarroll J, et al. Beta III tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells. Carcinogenesis 2016; 37: 787–98.
Panda D, Miller H, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Nat Acad Sci USA 1994; 91: 11358–62.
Jensen-Smith H, Eley J, Steyger P, et al. Cell type-specific reduction of beta tubulin isotypes synthesized in the developing gerbil organ of Corti. J Neurocytol 2003; 32: 185–97.
Dráberová E, Del Valle L, Gordon J, et al. Class III β-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J Neuropathol Exp Neurol 2008; 67: 341–54.
Katsetos C, Draber P, Kavallaris M. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011; 11: 719–28.
Foudah D, Monfrini M, Donzelli E, et al. Expression of neural markers by undifferentiated mesenchymal-like stem cells from different sources. J Immunol Res 2014; 2014: 987678–94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
